Perineural Dexamethasone in the Adductor Canal Block

Sponsor
Olfa kaabachi, MD (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06079047
Collaborator
(none)
66
1
2
25.6
2.6

Study Details

Study Description

Brief Summary

Postoperative pain management in total knee arthroplasty (TKA) surgery is a real challenge for the anesthesiologist. Effective pain control must be provided while preserving the mobility to ensure early rehabilitation. The adductor canal block is an effective way to induce sensory block without motor block. However, the major disadvantage of this block is the duration of sensory block which may be insufficient for postoperative pain management in TKA surgery. Many studies have focused on finding molecules that can prolong sensory block without the need for a perineural catheter and dexamethasone is among the most studied molecules(1, 2). Hence, our study aims to evaluate the added value of perineural dexamethasone in the adductor canal block in TKA surgery.

[

Condition or Disease Intervention/Treatment Phase
  • Procedure: group Dexamethasone
  • Procedure: group Controle
N/A

Detailed Description

Using a computer-generated sequence of random numbers, the patients included will be randomly allocated to get an adductor canal block using :

Group D: 10 ml of 0.5% bupivacaine + 10 ml of 0.9% normal saline solution + 8 mg of dexamethasone (equivalent to 2 ml) Group C: 10 ml of 0.5% bupivacaine + 10 ml of 0.9% normal saline solution + 2 ml of 0.9% normal saline solution

All patients included in the study will initially be evaluated at the anesthesia outpatient clinic with correction of any existing health issues. A pre-anesthesia visit will be conducted the day before the procedure for all patients, providing them with information about the protocol of our study and obtaining their consent to participate.

Upon arrival at the operating room, non-invasive monitoring of blood pressure, pulse oximetry, and ECG tracing will be performed and also a blood glucose level measurement. An 18-gauge peripheral intravenous line will be established, and 0.03 mg per kg midazolam was administrated.

All patients will receive spinal anesthesia. Depending on the patient's condition, investigators will opte for:

A single shot spinal anesthesia using 0.5% bupivacaine (11 mg) with fentanyl (25 µg) for patients under 65 years of age with ASA I and II Continuous spinal anesthesia with drug titration for patients over 65 years of age or with ASA III classification.

None of patients will receive intravenous dexamethasone during the perioperative period.

The decision to use a tourniquet and use of cement will be left to the surgeon. In the immediate postoperative period, all patients will receive an adductor canal block with a high-frequency probe. The patients will be positioned in a supine position with the leg slightly externally rotated. The probe will be placed transversely on the inguinal fold. The femoral vessels (artery and vein) will be identified. The different muscular structures delimiting the adductor canal will be visualized: the sartorius muscle that covers the femoral artery and the medial vastus muscle laterally. The saphenous nerve, which is usually hyperechoic, is located most often at the lateral edge of the artery in the fascia between the sartorius and medial vastus muscles. A 100 mm neurostimulation needle was used and 22 ml solution was injected into the adductor canal.

Patients will be transferred to continuous care unit for 48 hours.

Post operative analgesia will include:
  1. Paracetamol 1g IV every 6 hours for 1 day then oral paracetamol 1g every 8 hours for 4 weeks

  2. Diclofenac sodium (50 mg) *2 per day for 5 days

  3. PCA morphine (Patient Controlled Analgesia), as a rescue analgesia. The first rise will be allowed on day 1 (18 h postoperatively) and the patient will be asked to wander with a walking frame for a distance of at least 3 meters (about 10 steps).

The patient will be considered ready for discharge after completing protocol endpoints and walking at least 3 meters without support.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Perineural Dexamethasone in the Adductor Canal Block for Postoperative Pain in Knee Arthroplasty Surgery
Anticipated Study Start Date :
Dec 15, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Jan 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: group Dexamethasone

adductor canal block with 10 ml of 0.5% "bupivacaine" + 10 ml of 0.9% saline solution + 2 ml of "dexamethasone" (8 mg)

Procedure: group Dexamethasone
Adductor canal block with dexamethasone

Active Comparator: group Controle

adductor canal block with 10 ml of 0.5% "bupivacaine" + 10 ml of 0.9% saline solution + 2 ml of 0.9% saline solution

Procedure: group Controle
Adductor canal block with saline solution

Outcome Measures

Primary Outcome Measures

  1. morphine consumption [48 hours]

    postoperative consumption of morphine

Secondary Outcome Measures

  1. NRS at rest [1 hour, 3 hours, 6 hours, 9 hours,12 hours, 24 hours, 36 hours and 48 hours postoperatively]

    Numerical rate scale at rest [ NRS =0 no pain ; NRS =10 worse pain]

  2. NRS on mouvement [1 hour, 3 hous, 6 hours, 9 hours,12 hours, 24 hours, 36 houes and 48 hours postoperatively]

    Numerical rate scale during knee flexion [ NRS =0 no pain ; NRS =10 worse pain]

  3. knee mouvement [preoperatively, on day 1 and day 7 postoperatively]

    Range of mouvement of the knee

  4. walk [day 1 and day 2 postoperatively]

    Numbers of steps

  5. Patient's satisfaction [48 hours postoperatively]

    3 level scale :0: not satisfied; 1: mild satisfaction; 2: satisfied

  6. Blood glucose level [1 hour, 6 hours,12 hours,18 hours, 24 hours postoperatively]

    Blood glucose level

  7. pain at home [7 days postoperatively]

    NRS at mouvement [ NRS =0 no pain ; NRS =10 worsE pain]

  8. quality of recovery [day one]

    QoR15 score [ 136-150 excellent recovery - 0-89 poor recovery]

  9. neuropathic Chronic pain [6 MONTHS]

    DN4 questionnaire [ no neuropathic pain 0 - neuropathic pain >4]

  10. chronic pain [6 months]

    NRS on mouvement [ NRS =0 no pain ; NRS =10 worse pain]

  11. postoperative quality of life [6 months]

    SF-12 score [0 to 100, with higher scores indicating better physical and mental health functioning]

  12. knee fonction [6 months]

    KOOS PS score [[0 to 100, with higher scores indicating better knee function]functioning]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients scheduled for unilateral TKA

  • Surgery under spinal anesthesia

  • ASA class I, II, and III patients

Exclusion Criteria:
  • Patient refusal to participate in the study

  • Contraindication to regional anesthesia

  • Allergies to the products used

  • Bilateral TKA

  • Revision TKA

  • TKA in the context of inflammatory or post-traumatic disease

  • BMI > 45

  • Poorly controlled diabetic patients with HbA1c > 8%

  • Patients on corticosteroid therapy or who have received an intra-articular injection of corticosteroids

Contacts and Locations

Locations

Site City State Country Postal Code
1 KAABACHI Tunis La Mannouba Tunisia 2010

Sponsors and Collaborators

  • Olfa kaabachi, MD

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Olfa kaabachi, MD, PROFESSOR, University Tunis El Manar
ClinicalTrials.gov Identifier:
NCT06079047
Other Study ID Numbers:
  • CE-IMKO- 111/2023
First Posted:
Oct 12, 2023
Last Update Posted:
Oct 12, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Olfa kaabachi, MD, PROFESSOR, University Tunis El Manar
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2023